Gastrointestinal (GI) carcinomas represent a heterogeneous composition of malignancies that stem from the organs of the GI tract. They are among the most prevalent and are associated with high mortality alongside morbidity rates. This study utilized the guidelines set forth by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), whereby four medical databases were searched for relevant scholarly publications published between 2010 and 2024. These databases were PubMed, Web of Science, and ScienceDirect. Risk of bias (RoB) for cohort, case-controlled, and cross-sectional studies was assessed using the Newcastle-Ottawa Scale (NOS), whereas randomized controlled trials (RCTs) used the Cochrane (RoB) tool. With the assumption that the observed estimate of the treatment effect differs between the included studies, a random effect meta-analysis was carried out. In the meta-analysis, fifteen trials with 7607 patients were considered. The findings indicate a substantial correlation between high-grade tumor budding and tumor stage, (χ²=480472.97, P<0.00001) with a mean difference of -6.18 at 95% confidence interval (95% CI) (-14.66 to 2.30), tumor differentiation (χ²=23.31, P<0.00001) with a mean difference of -12.60 at 95% CI (-35.89 to 10.68), lymph vascular invasion (χ²=29.59, P<0.00001) with a mean difference of -5.03 at 95% CI (-11.26 to 1.21), and lymph node metastasis (χ²=158.30, P<0.00001) with a mean difference of -3.44 at 95% CI (-4.72, -1.78). Furthermore, in upper gastrointestinal (UGI) patients, high-grade tumor budding was associated with a negative five-year overall survival (P<0.00001) and a mean difference of -0.09 at 95% CI (-0.20 to 0.02). In regards to the risk of bias, most of the retrospective, prospective, case-control, and cohort studies 10/14 were of satisfactory quality. Moreover, 5/7 of the clinical trials had a low risk of bias. However, the funnel plot indicated that there is a probability of publication bias in favor of tumor budding. The study revealed a significant link between tumor budding and key prognostic factors-overall survival, lymph node metastasis, tumor differentiation, and lymphovascular invasion-in upper gastrointestinal carcinomas. High-grade tumor budding is associated with poor clinicopathological characteristics and a five-year overall survival. Tumor budding may serve as a unique prognostic marker. To confirm these results, further research with larger preoperative UGI biopsies is recommended.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519758 | PMC |
http://dx.doi.org/10.7759/cureus.70422 | DOI Listing |
Sci Rep
January 2025
Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, 25 Daehakbyeong-Ro, Dong-Gu, Ulsan, 44033, South Korea.
Tumor budding is a significant prognostic factor in colorectal cancer (CRC) management and is graded as follows: 0-4 buds as low, 5-9 buds as intermediate, and > 10 buds as high. However, the specific prognostic difference between cases with 0 buds (BD0) and those with 1-4 buds (BD1) is not well established owing to a lack of comparative studies. This study aimed to examine and compare the rate of lymph node (LN) metastasis and prognosis by distinguishing between BD0 and BD1 within the low-grade category (0-4 buds) of tumor budding in submucosa (T1) and muscularis propria (T2) CRC.
View Article and Find Full Text PDFCureus
December 2024
Surgery, Shiga General Hospital, Moriyama, JPN.
Objective This study aims to investigate the risk factors for lymph node metastasis (LNM) and postoperative recurrence in patients undergoing surgery for pT1 colorectal cancer (pT1-CRC). Materials and methods We retrospectively analyzed 150 patients who underwent bowel resection with lymph node dissection for pT1-CRC at our department between September 2011 and December 2021. Univariate and multivariate analyses were performed to examine the effects of sex, depth of tumor invasion, venous invasion, lymphatic invasion, tumor budding (BD), and histological type on LNM and recurrence.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Pathology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, 252-0374, Kanagawa, Japan.
To investigate the functional role of S100A4 in advanced colorectal carcinoma (Ad-CRC) and locally advanced rectal carcinoma (LAd-RC) receiving neoadjuvant chemoradiotherapy (NCRT). We analyzed histopathological and immunohistochemical sections from 150 patients with Ad-CRC and 177 LAd-RC patients treated with NCRT. S100A4 knockout (KO) HCT116 cells were also used.
View Article and Find Full Text PDFHistopathology
December 2024
Department of Surgical Pathology and Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, Womens Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Aims: Our study aimed to further confirm the clinical significance of the tumour budding activity and cell nest size-based (TBNS) grading scheme in cervical squamous cell carcinomas (SCC).
Methods And Results: We applied the TBNS system to assess the prognostic value in an institutional cohort of well-annotated cervical SCC consisting of 312 consecutive cases with surgical resection, no neoadjuvant chemotherapy and higher than stage pT1a. We found that high budding activity, single cell and TBNS grade 3 were more frequently associated with a decreased overall survival (OS) time and disease-free survival (DFS) time (P < 0.
Cell Mol Biol Lett
December 2024
Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Background: Radiotherapy for pelvic malignant tumors inevitably causes intestinal tissue damage. The regeneration of intestinal epithelium after radiation injury relies mainly on crypt fission. However, little is known about the regulatory mechanisms of crypt fission events.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!